To print: Select File and then Print from your browser's menu

Title: Real-World Use of Fexofenadine Parallels Clinical Trials: Presented at EAACI

"Real-World Use of Fexofenadine Parallels Clinical Trials: Presented at EAACI"

By Jill Stein PARIS, FRANCE -- June 13, 2003 -- Treating allergic-rhinitis with fexofenadine in the real-world clinical setting delivers results that are in line with those reported in clinical trials, researchers announced here June 10th at the 22nd Congress of the European Academy of Allergology and Clinical Immunology. Claus Bachert, MD, PhD, from University Hospital of Ghent in Ghent, Belgium, presented findings from a post-marketing surveillance trial of fexofenadine that reviewed the clinical records of 13,007 patients with seasonal allergic rhinitis who were treated with the peripheral antihistamine fexofenadine. Overall, 5% of the cohort had mild disease, 54% had moderate disease, and 36% had severe disease. Information about disease severity was not available in 5% of patients. The researchers assessed symptoms of nasal obstruction, eye complaints, nose itching, rhinorrhoea and sneezing. Median time since the first occurrence of seasonal allergic rhinitis was 5 years, and mean treatment duration was 22 days. Fexofenadine treatment was associated with a marked decrease in severity of all five symptoms (P

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.